What do systematic reviews say?

Higher blood flow vs standard blood flow

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 499 participants
  Low

Higher blood flow vs standard blood flow

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Higher blood flow vs standard blood flow

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Higher blood flow vs standard blood flow

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Combined low‐dose OCP vs another combined low‐dose OCP

It is very uncertain whether combined low‐dose OCP changes absence from work or school compared with another combined low‐dose OCP (very low certainty).

• Combined oral contraceptive pill for primary dysmenorrhoea 2023 · Cochrane Headline outcomes only
  RR 1.12 [0.64, 1.99]
  1 study · 445 participants
  Very low

Combined low‐dose OCP vs another combined low‐dose OCP

• Combined oral contraceptive pill for primary dysmenorrhoea 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 106 participants
  Low

Combined low‐dose OCP vs another combined low‐dose OCP

Combined low‐dose OCP showed no clear difference in pain improvement compared with another combined low‐dose OCP (moderate certainty).

• Combined oral contraceptive pill for primary dysmenorrhoea 2023 · Cochrane Headline outcomes only
  RR 1.06 [0.65, 1.74]
  1 study · 326 participants
  Moderate

Combined low‐dose OCP vs another combined low‐dose OCP

Combined low‐dose OCP may leads to higher adverse events for continuous vs standard regimen OCP compared with another combined low‐dose OCP (low certainty).

• Combined oral contraceptive pill for primary dysmenorrhoea 2023 · Cochrane Headline outcomes only
  RR 1.11 [1.01, 1.22]
  3 studies · 602 participants
  Low

Combined low‐dose OCP vs another combined low‐dose OCP

The review found no eligible studies for this question.

• Combined oral contraceptive pill for primary dysmenorrhoea 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low‐intensity pulsed ultrasound vs control

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 393 participants
  Very low

Low‐intensity pulsed ultrasound vs control

The review found no eligible studies for this question.

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low‐intensity pulsed ultrasound vs control

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 370 participants
  Low

Low‐intensity pulsed ultrasound vs control

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 887 participants
  Very low

Low‐intensity pulsed ultrasound vs control

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 148 participants
  Very low

Low‐intensity pulsed ultrasound vs control

Low‐intensity pulsed ultrasound showed no clear difference in delayed or non‐union (medium term) compared with control (moderate certainty).

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  RR 1.25 [0.5, 3.09]
  7 studies · 746 participants
  Moderate

Low‐intensity pulsed ultrasound vs control

It is very uncertain whether low‐intensity pulsed ultrasound changes adverse events Reported as skin irritation compared with control (very low certainty).

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  RR 0.94 [0.06, 14.65]
  1 study · 101 participants
  Very low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.25, 2.46]
  3 studies · 162 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.52, 1.12]
  3 studies · 238 participants
  Moderate